Medidata Solutions price target raised to $55 from $47 at Stifel Stifel increased its price target on Medidata as the firm thinks the company has a strong platform and robust analytics. The firm believes the company has a number of other positive catalysts and is well-positioned to deliver strong growth. Stifel expects the company to report favorable Q2 results and keeps a Buy rating on the shares.
Medidata Solutions COO appointment positive, says JPMorgan JPMorgan views Medidata's addition of Michael Capone in the newly created role of COO as a positive, as Capone should be able to help the company scale and should free up the company's CEO and President to focus on strategy and big deals. The firm maintains its Overweight rating on the stock.
Medidata Solutions initiated with an Overweight at JPMorgan JPMorgan believes software dedicated to the clinical trial process will be in high demand for years to come. The firm started shares of Medidata Solutions with an Overweight rating and $60 price target.